首页|糜蛋白酶联合特布他林雾化治疗支气管哮喘的临床效果

糜蛋白酶联合特布他林雾化治疗支气管哮喘的临床效果

扫码查看
目的 探讨糜蛋白酶联合特布他林雾化治疗支气管哮喘的疗效及其对肺功能、炎性因子、免疫球蛋白水平的影响.方法 将80例支气管哮喘患者随机分为对照组40例与观察组40例.2组均予以常规治疗,在此基础上对照组给予特布他林雾化治疗,观察组给予糜蛋白酶联合特布他林雾化治疗.比较2组临床疗效、临床症状消失时间及治疗前后肺功能指标[第1秒用力呼气容积(FEV1)、FEV1/用力肺活量(FVC)、呼出气一氧化氮(FENO)]、血清炎性因子水平[嗜酸细胞阳离子蛋白(ECP)、γ干扰素(IFN-γ)、白细胞介素-4(IL-4)、白细胞介素-1β(IL-1β)、超敏C反应蛋白(hs-CRP)]、免疫球蛋白水平[免疫球蛋白A(IgA)、免疫球蛋白M(IgM)、免疫球蛋白G(IgG)、免疫球蛋白E(IgE)]的变化;观察2组治疗期间不良反应发生情况.结果 观察组治疗总有效率较对照组显著增加(P<0.05),症状消失时间较对照组显著缩短(P<0.05).2组治疗后FENO值及血清ECP、IL-4、IL-1β、hs-CRP、IgE水平均较治疗前显著降低,FEV1、FEV1/FVC值及血清IFN-γ、IgA、IgM、IgG水平均较治疗前显著升高,且观察组治疗后上述指标较对照组治疗后改善更为显著,差异均有统计学意义(P<0.05).2组治疗期间不良反应发生率比较差异无统计学意义(P>0.05).结论 糜蛋白酶联合特布他林雾化治疗支气管哮喘疗效确切,可在短时间内改善临床症状,促进肺功能恢复,缓解炎性反应,改善免疫功能.
Clinical Efficacy of Chymotrypsin Combined with Terbutaline Nebulization in Bronchial Asthma
Objective To investigate the efficacy of chymotrypsin combined with terbutaline nebulization in the management of bronchial asthma and its effect on lung function,inflammatory factors,and immunoglobulin levels.Methods 80 patients with bronchial asthma were randomly divided into the control group and the observation group,40 cases in each group.On the basis of conventional treatment for both groups,the control group was further given terbutaline nebuliza-tion whereas the observation group was given chymotrypsin combined with terbutaline nebuliza-tion treatment.Clinical efficacy,clinical symptom disappearance time,pulmonary function indexes[forceful expiratory volume in the first second(FEV1),FEV1/forceful lung capacity(FVC),ex-haled nitric oxide(FENO)],serum inflammatory factors[ECP,IFN-γ,interleukin-4(IL-4),inter-leukin-1β(IL-1β),hypersensitive C-reactive protein(hs-CRP)],and immunoglobulin levels[im-munoglobulin A(IgA),immunoglobulin M(IgM),immunoglobulin G(IgG),immunoglobulin E(IgE)]were compared before and after the treatment between the two groups.The occurrence of adverse reactions was observed in the 2 groups.Results The total effective rate of the observation group was higher than that of the control group(P<0.05).Symptom disappearance time of the observation group was shorter than that of the control group(P<0.05).The FENO value and ser-um ECP,IL-4,IL-1β,hs-CRP,IgE levels of the two groups were significantly lower after treat-ment than those before treatment;the FEV1,FEV1/FVC values and serum IFN-γ,IgA,IgM,IgG levels were significantly higher than those before treatment;the above indexes of the observation group were more significantly improved after treatment than those of the control group,and the differences were statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Chymotryp-sin combined with terbutaline nebulization might be effective in the management of bronchial asthma,which can positively alleviate clinical symptoms,promote pulmonary function,improve inflammatory response and immune function in a short period of time,with relatively good safety.

bronchial asthmachymotrypsinterbutalineclinical efficacypulmonary functioninflammatory factorimmunoglobulin

薛绍芬、田英、陈雅

展开 >

郑州市第九人民医院呼吸科,郑州 450000

支气管哮喘 糜蛋白酶 特布他林 临床疗效 肺功能 炎性因子 免疫球蛋白

2024

实用临床医学
南昌大学

实用临床医学

影响因子:0.818
ISSN:1009-8194
年,卷(期):2024.25(2)
  • 15